what's next

With our proprietary GRIFFIN Deep Genomics Platform, Quantgene is developing a pipeline of early-detection and oncology products.

We are poised to launch the first Deep Genomics-based early-cancer detection solution in early 2020o

Stay Up-to-date

Pioneering what's next

Quantgene is engaged in clinical trials to validate the early cancer detection capabilities of our technology. We are excited to announce that we see promising interim results from our feasibility trial.

Our Cancer detection pipeline includes:
• Pancreatic Cancer
• Gastric Cancer
• Lung Cancer
• Colorectal Cancer
• Multi-Cancer

Stay Up-to-date

Ready to fast-track your research?

Our team is ready to help